Vyome (NASDAQ:HIND) reported first-quarter 2026 results and highlighted continued progress toward advancing its lead clinical program, VT-1953, while emphasizing what management described as a disciplined capital structure and spending approach.
On the company’s June 3 earnings call, Chief Executive Officer Venkat Nelabhotla said the quarter was “another important period of disciplined execution and continued progress” for Vyome Holdings following its Nasdaq listing. He said the company has spent recent quarters building around “differentiated immunoinflammatory and rare disease opportunities” while maintaining what he called “an extremely clean capital structure.”
“We believe maintaining this discipline is critical for long-term shareholder value and alignment and institutional credibility,” Nelabhotla said.
VT-1953 Remains Primary Development Focus
Vyome’s lead program, VT-1953, is being developed for signs and symptoms associated with malignant fungating wounds. Nelabhotla said the condition has substantial unmet medical need and no FDA-approved therapy specifically addressing it.
During the quarter, the company made regulatory submissions to the U.S. Food and Drug Administration related to pivotal development readiness for VT-1953. Those submissions included proposals involving manufacturing, toxicology, pharmacokinetic requirements and clinical development considerations, according to Nelabhotla.
The company also filed an orphan drug designation application with the FDA for the VT-1953 program. In addition, Vyome presented positive Phase 2 clinical study data for VT-1953 at the American Association for Cancer Research 2026 conference in San Diego. Nelabhotla said the presentation received “very positive feedback” at the meeting.
Nelabhotla said independent analysts estimate the U.S. total addressable market opportunity for the indication at more than $2 billion. He also emphasized the patient burden associated with malignant fungating wounds, describing them as “one of the most underserved and emotionally distressing conditions in advanced cancer care.”
“One important point I would like to underscore is that malignant fungating wounds remain one of the most underserved and emotionally distressing conditions in advanced cancer care, affecting not only physical symptoms such as odor, pain, but also dignity, emotional well-being, and quality of life for both patients and caregivers,” Nelabhotla said.
Company Expands Immunoinflammatory Strategy
In addition to VT-1953, management said Vyome used the quarter to continue development activities around VT-1908 and its broader immunoinflammatory strategy.
Nelabhotla discussed the company’s previously announced strategic in-licensing agreement with Impetis Biosciences Limited, a Tata Enterprise, involving selective JAK inhibitor assets. He said the agreement opens an opportunity in a $57 billion total addressable market and reflects Vyome’s focus on capital-efficient access to innovation.
According to Nelabhotla, the agreement includes no upfront payments and no milestone obligations beyond back-end royalties tied to commercialization. He said the opportunity does not change Vyome’s primary focus on VT-1953 or its approach to disciplined capital allocation.
During the question-and-answer portion of the call, Theodore O’Neill of Litchfield Hills Research asked for more information about the Impetis agreement, including the potential indications for the JAK inhibitors and whether additional milestones were expected in 2026.
Nelabhotla said the assets are preclinical and that early development had been focused more on atopic disease, psoriasis and autoimmune diseases. He said Vyome is evaluating other possible indications, including rare disease opportunities, through non-dilutive pathways.
“It is, at this time, completely an open book,” Nelabhotla said. “The strategic discussions are happening inside, and it will take a couple of quarters to figure that out.”
Asked what investors might expect over the next 12 to 24 months, Nelabhotla said the company may do some work using non-dilutive pathways, but that its capital remains focused on VT-1953 and a planned late-stage trial. He said investors could see “some news development and publications,” but added that no clear plan has been finalized and that management would need to discuss the matter with the board.
First-Quarter Financial Results
Chief Financial Officer Robert Dickey said Vyome ended the quarter with cash and cash equivalents of approximately $8.8 million, compared with approximately $5 million as of Dec. 31, 2025. Total assets were approximately $10.2 million as of March 31, 2026, and total stockholders’ equity was approximately $8 million.
Total operating expenses for the quarter were approximately $1.15 million. Research and development expenses were approximately $660,000, while selling, general and administrative expenses were approximately $478,000.
The company reported a net loss attributable to common shareholders of approximately $963,000, or approximately $0.15 per basic and diluted share, for the quarter ended March 31, 2026.
Vyome also raised approximately $5.29 million through the sale of 1,089,545 common shares on Jan. 27, 2026, at an average price of $5 per share. Nelabhotla said the sale represented a 59.2% premium to the prior day’s closing price and resulted in total dilution to existing shareholders of approximately 15%.
Management Emphasizes Cash Discipline
Dickey said the company continued strengthening governance processes and completing public company reporting and compliance milestones during the quarter and subsequent period. He also reiterated the significance of the reduction in authorized common shares from 300 million to 50 million shares.
“Looking ahead, we remain focused on prudent cash management while continuing to support key regulatory, manufacturing, and development activities associated with VT-1953 and our broader pipeline initiatives,” Dickey said.
In closing remarks, Nelabhotla said Vyome’s priorities remain advancing VT-1953 “responsibly and thoughtfully” toward its next development stages while maintaining disciplined capital allocation and focusing on long-term shareholder value creation.
About Vyome (NASDAQ:HIND)
ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.
